Royal Bank Of Canada Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $465.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective cut by equities researchers at Royal Bank Of Canada from $500.00 to $465.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 27.24% from the company’s current price.

Other analysts also recently issued reports about the company. Needham & Company LLC raised their target price on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Leerink Partners reduced their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Wells Fargo & Company dropped their price target on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. Finally, Jefferies Financial Group decreased their price objective on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $485.21.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $365.46 on Tuesday. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $495.55. The stock has a market cap of $48.28 billion, a PE ratio of 1,522.75 and a beta of 0.32. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The stock has a 50 day moving average price of $413.42 and a 200 day moving average price of $422.65.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the sale, the chief executive officer owned 78,411 shares in the company, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 56,955 shares of company stock valued at $24,072,733. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Yousif Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after purchasing an additional 29 shares in the last quarter. Sivik Global Healthcare LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $1,193,000. Ascent Group LLC increased its stake in shares of Alnylam Pharmaceuticals by 27.4% during the fourth quarter. Ascent Group LLC now owns 795 shares of the biopharmaceutical company’s stock worth $316,000 after buying an additional 171 shares during the period. Perpetual Ltd acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $2,004,000. Finally, Sara Bay Financial raised its holdings in Alnylam Pharmaceuticals by 20.7% in the fourth quarter. Sara Bay Financial now owns 1,750 shares of the biopharmaceutical company’s stock valued at $695,000 after acquiring an additional 300 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.